A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...
Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.
A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Medical Xpress on MSN6d
Ozempic And Other GLP-1s Show Promise With 42 Conditions — But There Are Still Big RisksSeveral years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results